$3.2M Pours on Parasol Therapeutics

Xconomy Boston — 

Parasol Therapeutics, a Cambridge, MA-based developer of treatments and diagnostics for influenza and other viruses, has raised $3.2 million in debt and equity financing, according to an SEC filing. Parasol, which Xconomy reported has previously raised $3.5 million in seed financing, is developing new therapies for flu based on discoveries in the MIT lab of professor Ram Sasisekharan related to how viruses attach to sugar chains on the surfaces of cells to infect them. Previous investors in the startup include initial backer Polaris Venture Partners, of Waltham, MA, Flagship Ventures, in Cambridge, and Lux Capital in New York. Polaris officials have not yet responded to a request for comment on this financing.